Pfizer and Flynn Pharma fined €101 million for charging the UK health service excessive prices for Phenytoin sodium capsules, an anti-epilepsy drug

by Dechert LLP
Contact

Dechert LLP

The UK Competition and Markets Authority (“CMA”) recently published its infringement decision of 7 December 2016 that imposed a fine on Pfizer1 and Flynn Pharma2 (“Flynn”) for abusing their respective dominant positions by charging excessive and unfair prices for phenytoin sodium capsules (“Phenytoin”).

In Europe, Aspen Pharmacare was recently fined by the Italian Competition Authority for similar practices, and is currently under investigation by the European Commission (“Commission”) for having allegedly implemented excessive prices in several EU Member states on five cancer drugs.

This sends a very clear message to pharmaceutical companies: competition authorities in the EU are willing to investigate drugs’ price levels in spite of national price regulations set by health authorities.

Summary of CMA’s findings

In 2012, Pfizer sold its UK Market Authorizations (“MAs”) for its Phenytoin brand Epanutin to Flynn, a pharmaceutical company specializing in the acquisition of so-called “end of life” products. Pfizer received a nominal fee of £13 and continued to manufacture its Phenytoin capsules, which it supplied exclusively to Flynn at prices that were up to 1,600% higher than what it charged customers prior to the transfer. At that time, the prices of Epanutin were regulated in the UK as part of Pfizer’s portfolio of branded drugs under the National Health Service (“NHS”) Pharmaceutical Price Regulation Scheme (“PPRS”).4

Flynn subsequently requested and obtained from the Medicines and Healthcare Products Regulatory Agency (“MHRA”) the approval to de-brand Epanutin. Consequently, the drug was withdrawn from the PPRS which allowed Flynn to significantly increase its prices.

Two product characteristics of Phenytoin severely limit customers’ ability to switch between different brands, namely its narrow therapeutic index and non-linear pharmacokinetics. These features mean that even small changes to the dose delivered to the circulation can give rise to a disproportionate change in drug’s level in the body. This may lead to therapeutic failure and toxic side effects, including the loss of seizure control. As a result, clinical guidance issued by the National Institute for Health and Care Excellence (“NICE”) and the Medicines and Healthcare Products Regulatory Agency (“MHRA”) recommends that patients who are stabilised on a particular manufacturer’s Phenytoin should not be switched to another manufacturer’s product.

The difficulties in switching to another brand meant that Flynn was able to increase the price it charged UK customers by up to 2,600% (while the price of Epanutin remained unchanged in other EU countries). This led to an annual increase of NHS’s expenditure on this product totalling €54 million.

The CMA opened a formal investigation in May 2013 following a complaint by the UK Department of Health (“DH”) that was lodged in September 2012.

CMA’s characterization of the excessive prices

The CMA’s infringement decision covers the excessive prices that Flynn was charged by Pfizer, and the excessive prices that Flynn charged its customers. It found that Pfizer and Flynn’s pricing practices constituted an abuse of their dominant position on the market for the manufacture of Phenytoin distributed in the UK and the market for the distribution of Phenytoin in the UK, respectively.

The CMA applied the cumulative two-stage test set forth by the European Court of Justice in its United Brands judgment to assess whether a price is unfairly high. The test involves assessing whether (i) the difference between the costs actually incurred and the price actually charged is excessive; and if so, (ii) whether a price has been imposed which is unfair either in itself or when compared to competing products.

In order to determine whether the difference between the product costs and the prices charged by Pfizer and Flynn were excessive, the CMA used the following benchmarks: (i) the rate of return of both companies on products other than Epanutin (between 5% and 19%); (ii) the target rate of return set by the PPRS (6%); and (iii) the rate of return of other pharmaceutical companies selling off-patent drugs (between 16.4% and 25.1%). The CMA’s assessment was also guided by the Commission’s infringement decision in Deutsche Post in which the imposition of a price 25% above the costs reasonably attributable to the product (i.e., the excess) was found to be excessive; and the judgment of the UK Competition Appeal Tribunal (“CAT”) in Albion Water II where an excess of at least 46.8% was considered excessive.

Based on the above factors, the CMA concluded that the prices charged by Pfizer to Flynn, and the prices charged by Flynn to wholesalers and pharmacists were excessive. In Pfizer’s case, the excess, including a reasonable rate of return, ranged between 29% (for 25 mg capsules) and 690% (for 300 mg capsules). The excess in Flynn’s prices, including a reasonable rate of return, varied between 31% (for 100 mg capsules) and 133% (for 25 mg capsules).

The CMA found that the unfairness limb of the United Brands test was satisfied since the price increases were not justified by any significant change in the costs of production. In particular, notwithstanding the fact that all of Pfizer’s European supplies of Epanutin are manufactured at its plant in Germany, prices in other EU Member States were considerably lower than those charged to UK customers. On this basis, the CMA rejected Pfizer’s argument that Phenytoin was produced at a loss. Moreover, the price increases were not justified by any significant changes in the costs of supply since the distribution of Phenytoin into the UK was undertaken by a third party (as opposed to Flynn) or by any new product-specific risks or innovation costs.

As part of its assessment, the CMA also relied on the parties’ contemporaneous internal documents as evidence. Those documents revealed that both parties pursued a common aim during negotiations for the transfer of Pfizer’s UK Phenytoin MAs, namely mitigating the risk of Pfizer suffering any reputational damage due to the price increases by deflecting negative customer reactions from Pfizer to Flynn. According to the CMA, Pfizer and Flynn were aware that the price increases would necessarily have an adverse effect on both (i) the NHS’s budget, and (ii) Epanutin users, since the NHS is required to procure the product for a category of patients under the UK health agencies’ clinical guidance.

Fines and remedies

The CMA fined Pfizer and Flynn approximately €95 million and €6 million, respectively. Due to the personal involvement of Flynn’s directors and senior management, in particular its CEO and Director, in the planning and implementation of the infringement, the CMA increased Flynn’s fine by an amount which was not disclosed in the public version of the decision.

In addition to the fines, the CMA’s directions ordered both companies to reduce their prices within 30 days. Although the directions stipulated that the Parties should be guided by the CMA’s decision when setting their revised prices, the CMA did not go as far as setting a price noting that it is not a price regulator and that the parties are responsible for assessing their own compliance with competition law. The companies were also ordered to notify the CMA of any price changes for a period of 10 years following the issue of the directions.

Both companies are currently appealing the CMA’s decision to the CAT. Flynn also made an unsuccessful application for interim relief to prevent the CMA’s directions from taking effect pending the outcome of its appeal arguing that it stood to suffer serious and irreparable harm including financial losses, a potentially permanent effect on market prices and changes to the organization of its business. Although the CAT found that Flynn would suffer significant irrecoverable financial harm, it concluded that this was outweighed by the potential harm to patients and the NHS.

If CAT upholds the CMA’s decision, several potential claimants, and in particular the NHS, may bring actions for damages against Pfizer and Flynn. The main hearing is scheduled to commence on 30 October, 2017.

Key Takeaways:

  • Due to political pressure, competition authorities seem to be willing to aggressively pursue excessive pricing cases in the pharmaceutical sector, a previously underused category of infringement; and
  • By referring to notions such as “excessive” or “reasonable” prices to determine whether pricing behaviour constitutes an abuse of dominance, the competition authorities have left themselves a significant margin of discretion.

Footnotes

1) In Pfizer’s statement issued on 7 December 2016, Pfizer indicated that “[i]t believes the CMA’s findings are wrong in fact and law and will be appealing all aspects of the Decision” (emphasis added). 

2) In Flynn's statement issued after the publication of the CMA’s infringement decision, Flynn indicated that “Flynn will appeal to overturn the CMA’s findings in the courts. We are confident the CMA’s findings will be overturned” (emphasis added).

3) Competition Appeal Tribunal, 19 January 2017, Flynn Pharma Limited vs CMA (interim relief judgement), § 14.

4) PPRS is a voluntary agreement between the UK Government and the pharmaceutical industry, whose. Its dual aim is to regulate the price of branded products while allowing pharmaceutical companies to make a reasonable profit.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Written by:

Dechert LLP
Contact
more
less

Dechert LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.